Physician profile
Richard Whitlock
NPI 1053335828
$10,900.46
in general payments reported to CMS, 2019-2025
30 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $213 · 2021: $69.28 · 2022: $609 · 2023: $7,450 · 2024: $743 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,000 · Travel and Lodging: $838 · Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,000.00 |
| Travel and Lodging | $837.54 |
| Food and Beverage | $817.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $8,244.36 | 2022-2025 | Atriclip Laa Exclusion System |
| Pfizer INC. | $513.18 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $335.71 | 2019-2023 | Xarelto |
| Amgen INC. | $294.97 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $280.22 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $187.48 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.74 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $112.45 | 2022-2023 | Camzyos |
| Boston Scientific Corporation | $99.88 | 2019-2024 | Watchman Flx, Watchman Access System |
| Astellas Pharma US INC | $71.54 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.11 | 2019 | |
| Philips North America LLC | $60.46 | 2020-2023 | |
| Angiodynamics, INC. | $50.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $49.82 | 2019 | |
| Merck Sharp & Dohme LLC | $49.68 | 2022-2024 | Verquvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.70 | 2019 | |
| Novo Nordisk INC | $45.24 | 2025 | Ozempic |
| Cardinal Health 200 LLC | $31.36 | 2019 | |
| Shockwave Medical, INC | $30.88 | 2022 | |
| Allergan, INC. | $23.53 | 2019 | |
| Abbott Laboratories | $20.06 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.59 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $18.31 | 2023 | Injectafer |
| Aegerion Pharmaceuticals, INC. | $17.55 | 2019 | |
| Amarin Pharma, INC. | $17.54 | 2020 | |
| Portola Pharmaceuticals, LLC | $16.53 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.50 | 2023 | Inpefa |
| Medtronic, INC. | $15.61 | 2022 | |
| Irhythm Technologies, INC. | $14.85 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $12.89 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Whitlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.